Targeted Therapeutics, LLC is a preclinical biopharmaceutical company developing novel therapeutics that target cancer cells by disrupting multiple signaling pathways that cancer cells depend on for survival. The Company’s TT-101 combination drug induces mitosis-related death in proliferating cancer cells and blocks mitotic entry in healthy cells leaving them unaffected.
Targeted Therapeutics has validated the performance of TT-101 in preclinical studies with pancreatic cancer and NSCLC cells in vitro and in mice. The Company is conducting additional preclinical studies including: an animal toxicology study to establish safe dosage for human testing; a drug efficacy study in mice to determine cancer types that are most sensitive to TT-101 to provide a basis for selecting clinical trial patients; and a pharmacodynamics study to determine the bioavailability and metabolism of TT-101.
Bill Ponton, MBA
Bill Ponton is CEO and co-founder of Targeted Therapeutics, LLC. He has also co-founded and led several biotech startups including US Biomarkers, a molecular diagnostics company providing biomarkers for cancer and neurodegenerative diseases based on methylation analysis of cell-free DNA in blood plasma. In addition, Bill assists early-stage biotech companies accelerate the development and commercialization of their products and services through his consulting firm, Princeton Venture Advisory. Prior to his involvement in biotech, he worked and invested in several successful technology startups in the digital video space. Earlier in his career, he served on the staff of Princeton University in the Plasma Physics Lab. Mr. Ponton holds an MBA from NYU Stern School of Business and a B.S. degree in Electrical Engineering from Rutgers University.
Victor Levenson, M.D., PhD.
Victor Levenson, MD, PhD, is the CSO and co-founder of Targeted Therapeutics, LLC. He received his MD from the Pirogov’s Second Moscow State Medical Institute in Moscow, USSR and PhD from the Institute of Molecular Biology in Moscow, USSR in the field of Molecular and Cellular Biology. Dr. Levenson has held faculty positions at the Institute of Molecular Biology (Moscow, USSR) in Molecular and Cellular Biology, University of Illinois at Chicago, Northwestern University, and Rush University Medical Center.
Dr. Levenson is a co-Founder of CDI Bioscience, Inc. a company providing products and services that enhance biopharmaceutical production and US Biomarkers, Inc., a molecular diagnostics company providing accurate, disease-specific biomarkers for cancer and neurodegenerative diseases through methylation analysis of cell-free DNA in blood.
He has received numerous awards, including two American Cancer Society Young Investigator awards, a National Institutes of Health FIRST Award, and three Susan G. Komen For the Cure awards for research into mechanisms of programmed cell death as related to resistance to chemotherapeutic agents. The genetic and epigenetic mechanisms for developing drug resistance, the relationship between cell cycle and cell death, and the regulation of mitotic cycle have been the focus of his work for many years. Dr. Levenson is one of the authors of a seminal paper on autophagy, a novel type of programmed cell death closely linked to drug resistance. Dr. Levenson was the Principal Investigator on multiple grants, has published more than thirty peer-reviewed articles, reviews, and book chapters, and has presented at numerous scientific meetings.